Navigation Links
Avamere Health Systems Announces New President of Signature Home Health
Date:1/24/2008

Trey Malicoat to lead both Signature Home Health and Signature Hospice

WILSONVILLE, Ore., Jan. 24 /PRNewswire/ -- Avamere Health Systems CEO Bob Schneider and COO Brent Hutchings have announced today that Trey Malicoat, president of Avamere's Signature Hospice, will also assume the leadership of Signature Home Health.

Malicoat, who has been with Avamere since 2005, will refocus the $12 million company on individualized needs for services. He will be responsible for providing more direct service workers and streamline management systems at Signature Home Health by using the same model he employs at Signature Hospice. Malicoat will oversee the trained staff of 200 nurses, social workers, home health aids and physical therapists in this new home care model designed to serve communities throughout the entire Pacific Northwest.

Chief of Operations of Signature Hospice Jane Brandes said she looks forward to the partnership. "Trey will increase the operation's organization and long term strategy for the hospice," she said.

"Trey's culture has led to this success," she said. "Providing more direct service workers and less middle management is the secret to our incredible growth and maintaining the highest standards of service. We offer individual care. If we need six people to serve one patient, we'll have six people there."

Signature Home Health's Chief of Operations Cheryl Lovell agrees. "We are going to make this the agency of the future," she said of Signature Home Health and Signature Hospice. "We will work together to bring the most excellent home health clinicians in the area to us. We are going to work together to be the health company in this market that delivers the highest quality of care."

Lovell said she is actively recruiting the most experienced clinicians with a passion about caring for people in their homes.

Signature Home Health provides skilled nursing, rehabilitation therapy, medical social work serv
'/>"/>

SOURCE Avamere Health Systems
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related medicine news :

1. Penn study finds pro-death proteins required to regulate healthy immune function
2. UCLA researchers identify markers that may predict diabetes in still-healthy people
3. Air pollution linked to cardiovascular risk indices in healthy young adults
4. More proof needed of safety and quality of electronic personal health records
5. Health care incentive model offers collaborative approach
6. Loneliness is bad for your health
7. Mailman School of Public Health study examines link between racial discrimination and substance use
8. Green Tea May Brew Up Healthier Skin
9. For Health Info, Women Often Turn to the Web
10. Record Number of Americans Lack Health Insurance
11. U.S. Research Funding Continues to Flatten as U.S. Health Costs Climb - in August 31 Science
Post Your Comments:
*Name:
*Comment:
*Email:
Breaking Medicine Technology:Reportlinker Adds Ion-Selective Clinical Lab Analyzers - Global Market Opportunities 2Reportlinker Adds Ion-Selective Clinical Lab Analyzers - Global Market Opportunities 3Reportlinker Adds Ion-Selective Clinical Lab Analyzers - Global Market Opportunities 4Reportlinker Adds Ion-Selective Clinical Lab Analyzers - Global Market Opportunities 5Veran Medical Receives FDA Clearance to Market Electromagnetic Navigated Bronchoscopy Product: The SPiN Drive(TM) System 2AMP Receives $1.4 Million Grant From the Bill & Melinda Gates Foundation to Improve Advocacy for VACCINES and Immunization Systems in West Africa 2AMP Receives $1.4 Million Grant From the Bill & Melinda Gates Foundation to Improve Advocacy for VACCINES and Immunization Systems in West Africa 3FDA Announces Plans for LASIK Quality of Life Project 59587 1FDA Announces Plans for LASIK Quality of Life Project 59587 2FDA Announces Plans for LASIK Quality of Life Project 59587 3FDA Warns of Unapproved and Illegal H1N1 Drug Products Purchased Over the Internet 59582 1FDA Warns of Unapproved and Illegal H1N1 Drug Products Purchased Over the Internet 59582 2FDA Warns of Unapproved and Illegal H1N1 Drug Products Purchased Over the Internet 59582 3BioMed Realty Trust to Report 2009 Third Quarter Results 59577 1BioMed Realty Trust to Report 2009 Third Quarter Results 59577 2
Other Medicine Technology:New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 2New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 3New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 4New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 5New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 6New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 7New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 8New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 9New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 10New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 11New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 12New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 13New Data on SEROQUEL XR(TM) in Treatment of Both Major Depressive Disorder and Generalized Anxiety Disorder Presented at APA Annual Meeting 14QRxPharma Releases Successful Phase 3 Study Results for 'Dual Opioid' Pain Therapy 2QRxPharma Releases Successful Phase 3 Study Results for 'Dual Opioid' Pain Therapy 3